-+ 0.00%
-+ 0.00%
-+ 0.00%

CANDEL THERAPEUTICS ANNOUNCES INITIATION OF GLOBAL PIVOTAL PHASE 3 AURORA TRIAL EVALUATING AGLATIMAGENE BESADENOVEC (CAN-2409) IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WITH INADEQUATE RESPONSE TO IMMUNE CHECKPOINT INHIBITORS

Reuters·06/30/2026 12:05:00

Please log in to view news